Stock comparison
Mettler-Toledo International
Neurocrine Biosciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
NBIX
Neurocrine Biosciences
Market cap
$15.91B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | NBIX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 68B | MTD |
| Benjamin Graham | 65B | 78B | NBIX |
| Philip Fisher | 63C | 80A | NBIX |
| Peter Lynch | 66B | 65B | MTD |
| Joel Greenblatt | 68B | 55C | MTD |
| Charlie Munger | 74B | 60C | MTD |
| Terry Smith | 70B | 63D | MTD |
Side-by-side metrics
| Metric | MTD | NBIX |
|---|---|---|
| Market cap | $22.29B | $15.91B |
| P/E (TTM) | 25.3x | 22.6x |
| EV/EBIT | 21.6x | 24.7x |
| ROIC (TTM) | 36.09% | 13.68% |
| Gross margin | 57.79% | 98.17% |
| Net margin | 21.4% | 21.55% |
| Revenue CAGR 5y | 2.01% | 26.04% |
| EPS CAGR 5y | 6.12% | 50.0% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 0.1x+100%
- ROIC (TTM)36.09%vs 13.68%+62%
- Market cap$22.29Bvs $15.91B+29%
- EV/EBIT21.6xvs 24.7x+12%
NBIX leads on
- Revenue CAGR 5y26.04%vs 2.01%+92%
- EPS CAGR 5y50.0%vs 6.12%+88%
- Gross margin98.17%vs 57.79%+41%
- P/E (TTM)22.6xvs 25.3x+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.